BHC: Bausch Health Cos., Inc.
About
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Current Value
$8.121 Year Return
Current Value
$8.121 Year Return
Key Details
Market Cap
$3.01B
P/E Ratio
-16.87
1Y Stock Return
19.07%
1Y Revenue Growth
10.91%
Dividend Yield
0.00%
Price to Book
-2.5
Strategies that include BHC
Stock's related to BHC
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MFIC | 45.38% | - | - | 10.93% |
| BLCO | 43.09% | $6.98B | +29.82% | 0.00% |
| ROP | 42.29% | $59.43B | +4.88% | 0.54% |
| SFL | 42.04% | $1.59B | -2.51% | 9.70% |
| PAYC | 41.67% | $12.69B | +27.90% | 0.66% |
| LW | 41.06% | $10.94B | -22.39% | 1.87% |
| BXMT | 39.39% | $3.25B | -15.37% | 12.33% |
| NYMT | 39.00% | $533.51M | -31.75% | 13.56% |
| MBC | 36.10% | $2.12B | +24.24% | 0.00% |
| TNL | 35.59% | $3.70B | +43.89% | 3.57% |
| PFLT | 35.22% | - | - | 11.12% |
| PEB | 35.21% | $1.56B | +5.95% | 0.30% |
| DEI | 35.14% | $3.19B | +66.93% | 3.98% |
| IVR | 34.61% | $492.52M | +2.14% | 19.60% |
| CPF | 34.57% | $849.01M | +79.56% | 3.30% |
| PRKS | 34.29% | $3.13B | +15.01% | 0.00% |
| MBUU | 34.28% | $829.22M | -8.01% | 0.00% |
| OFG | 34.28% | $2.04B | +31.90% | 2.17% |
| CLDT | 34.23% | $443.63M | -7.92% | 3.04% |
| DX | 34.13% | $990.50M | +9.56% | 12.62% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NEUE | 0.11% | $41.96M | -33.09% | 0.00% |
| AMED | -0.21% | $2.95B | -3.97% | 0.00% |
| WHLM | -0.21% | $19.81M | -14.82% | 0.00% |
| XBIT | -0.24% | $201.80M | +84.92% | 0.00% |
| NHTC | -0.28% | $64.47M | +3.99% | 13.82% |
| INSM | 0.33% | $13.20B | +211.04% | 0.00% |
| AIFU | -0.35% | $70.89M | -81.83% | 0.00% |
| KLG | 0.39% | $1.55B | +52.03% | 3.55% |
| OCFT | -0.40% | $81.68M | -30.63% | 0.00% |
| HUM | -0.42% | $35.61B | -42.65% | 1.19% |
| ASPS | 0.48% | $20.33M | -82.43% | 0.00% |
| JBSS | -0.51% | $959.03M | -10.37% | 1.03% |
| TEL | 0.53% | $45.03B | +14.61% | 1.26% |
| GCI | -0.54% | $759.17M | +153.69% | 0.00% |
| BCAN | -0.55% | $72.74M | -99.75% | 0.00% |
| MGPI | -0.65% | $1.03B | -49.60% | 1.02% |
| LTRN | -0.66% | $31.81M | -26.07% | 0.00% |
| ATNI | -0.67% | $306.82M | -34.58% | 4.73% |
| XGN | -0.75% | $69.14M | +151.28% | 0.00% |
| RNR | 0.76% | $13.75B | +22.34% | 0.58% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ANIK | -16.81% | $255.27M | -15.31% | 0.00% |
| QTTB | -13.41% | $329.37M | +172.64% | 0.00% |
| PRDO | -11.84% | $1.76B | +54.49% | 1.70% |
| CHKP | -11.82% | $20.02B | +26.88% | 0.00% |
| PRG | -10.37% | $1.93B | +71.63% | 1.04% |
| TPST | -10.27% | $39.00M | -78.67% | 0.00% |
| BNED | -9.68% | $270.40M | -91.94% | 0.00% |
| PULM | -9.57% | $22.32M | +230.27% | 0.00% |
| MCK | -8.91% | $79.75B | +37.34% | 0.41% |
| CSTE | -8.63% | $137.46M | +3.11% | 0.00% |
| MANH | -8.42% | $16.61B | +22.47% | 0.00% |
| TXO | -7.80% | $736.85M | -2.65% | 13.08% |
| BTCT | -7.27% | $58.86M | +395.83% | 0.00% |
| HUSA | -6.97% | $18.58M | -19.77% | 0.00% |
| QXO | -6.53% | $6.81B | -33.42% | 0.00% |
| HIHO | -6.32% | $8.50M | -1.53% | 6.22% |
| OXBR | -6.32% | $19.24M | +183.49% | 0.00% |
| MNOV | -6.23% | $98.09M | +5.26% | 0.00% |
| APEI | -6.14% | $347.33M | +194.00% | 0.00% |
| IMMP | -6.05% | $267.64M | -2.13% | 0.00% |
ETF's related to BHC
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VONV | 45.12% | $10.05B | 0.08% |
| SCHV | 44.97% | $12.03B | 0.04% |
| DFUV | 44.94% | $11.70B | 0.21% |
| IVOV | 44.87% | $957.55M | 0.15% |
| FSMD | 44.75% | $592.54M | 0.15% |
| IWP | 44.33% | $17.48B | 0.23% |
| IWD | 44.06% | $61.84B | 0.19% |
| PY | 43.84% | $77.99M | 0.15% |
| IUS | 43.12% | $623.60M | 0.19% |
| FTHI | 42.91% | $1.02B | 0.75% |
| AVUS | 42.78% | $7.76B | 0.15% |
| DFAC | 42.63% | $32.83B | 0.17% |
| FNDX | 42.39% | $17.60B | 0.25% |
| MDYV | 38.41% | $3.65B | 0.15% |
| PKW | 38.16% | $1.28B | 0.61% |
| DVAL | 37.74% | $120.08M | 0.49% |
| NUSC | 37.66% | $1.28B | 0.31% |
| DON | 37.64% | $3.93B | 0.38% |
| PAVE | 37.52% | $9.25B | 0.47% |
| JMEE | 37.48% | $1.52B | 0.24% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VGSH | 0.01% | $19.13B | 0.04% |
| DFNM | -0.24% | $1.40B | 0.17% |
| CCOR | -0.27% | $108.59M | 1.18% |
| IBTG | -0.32% | $1.49B | 0.07% |
| JPST | -0.48% | $28.45B | 0.18% |
| SPTS | -0.57% | $5.70B | 0.03% |
| SOYB | -0.62% | $27.32M | 0.22% |
| USCI | 0.75% | $185.92M | 1.07% |
| KCCA | 0.84% | $219.64M | 0.87% |
| XONE | -0.87% | $550.61M | 0.03% |
| UTWO | -0.91% | $442.66M | 0.15% |
| STPZ | 0.95% | $483.68M | 0.2% |
| AGZD | 1.24% | $142.85M | 0.23% |
| IBTF | 1.27% | $2.07B | 0.07% |
| IEI | 1.37% | $14.66B | 0.15% |
| MINT | 1.44% | $11.62B | 0.35% |
| DUSB | 1.66% | $812.64M | 0.15% |
| SCHR | 1.68% | $9.99B | 0.03% |
| FLDR | 1.73% | $604.50M | 0.15% |
| TYA | 1.84% | $124.65M | 0.17% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -24.43% | $195.31M | 0.85% |
| BTAL | -22.11% | $379.51M | 1.43% |
| TAIL | -19.45% | $68.06M | 0.59% |
| CORN | -14.76% | $61.32M | 0.2% |
| KRBN | -12.81% | $243.28M | 0.85% |
| UNG | -12.26% | $928.64M | 1.06% |
| USDU | -11.49% | $201.83M | 0.5% |
| FTSM | -11.27% | $6.07B | 0.45% |
| CTA | -10.93% | $359.48M | 0.78% |
| DBA | -9.05% | $768.98M | 0.93% |
| CLOI | -7.16% | $720.91M | 0.4% |
| WEAT | -7.06% | $123.26M | 0.28% |
| UUP | -6.64% | $359.07M | 0.77% |
| ULST | -6.34% | $535.66M | 0.2% |
| EQLS | -5.95% | $8.88M | 1% |
| BSCO | -4.94% | $2.31B | 0.1% |
| FTSD | -4.79% | $174.03M | 0.25% |
| IVOL | -4.78% | $549.88M | 1.02% |
| DFSD | -4.42% | $3.62B | 0.16% |
| YEAR | -4.19% | $1.14B | 0.25% |
News
Fintel
Bausch Health Companies (BHC) Price Target Increased by 12.41% to 7.48
Yahoo
The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan. The justices declined to hear an appeal by Norwich Pharmaceuticals of a lower court's ruling that its proposed generic would infringe patents owned by Bausch unit Salix Pharmaceuticals for using Xifaxan to treat the liver-related brain disorder hepatic encephalopathy.
Yahoo
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% ...
Yahoo
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix ...
SeekingAlpha
U.S. corporate credit markets delivered strong performance in the third quarter, as U.S. yields declined sharply and corporate credit spreads tightened.
Yahoo
Here is how Bausch Health (BHC) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.